Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters

References

• Smith TC. Toleration and bioavailability of gemfibrozil in healthy men. Proc R Soc Med. 1976;69(Suppl 2):24–27.
   PubMedGoogle Scholar
• Todd PA, Ward A. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs. 1988;36:314–339.
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–1245.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–418.
   PubMed Web of Science ®Google Scholar
• Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998;34:155–162.
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Kivistö KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000;68:122–129.
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Neuvonen M, et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 2002;72:685–691.
   PubMed Web of Science ®Google Scholar
• Backman JT, Luurila H, Neuvonen M, et al. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78:154–167.
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Kivistö KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001;69:340–345.
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 2003;73:538–544.
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455–463.
   PubMed Web of Science ®Google Scholar
• Whitfield LR, Porcari AR, Alvey C, et al. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol. 2011;51:378–388.
   PubMed Web of Science ®Google Scholar
• Mathew P, Cuddy T, Tracewell WG, et al. An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther. 2004;75:P33.
   Web of Science ®Google Scholar
• Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205–207.
   PubMedGoogle Scholar
• Shitara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004;311:228–236.
   PubMed Web of Science ®Google Scholar
• Wang J-S, Neuvonen M, Wen X, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002;30:1352–1356.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos. 2006;34:191–197.
   PubMed Web of Science ®Google Scholar
• Nakagomi-Hagihara R, Nakai D, Tokui T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007;37:416–426.
   PubMed Web of Science ®Google Scholar
• Sando KR, Knight M. Nonstatin therapies for management of dyslipidemia: a review. Clin Ther. 2015;37:2153–2179.
   PubMed Web of Science ®Google Scholar
• Guideline on the investigation of drug interactions. European Medicines Agency. 2012 [cited 2016 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
   Google Scholar
• Drug development and drug interactions: table of substrates, inhibitors and inducers. Food and Drug Administration. 2014 [cited 2016 Aug 4]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm
   Google Scholar
• Honkalammi J, Niemi M, Neuvonen PJ, et al. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther. 2012;91:846–855.
   PubMed Web of Science ®Google Scholar
• Backman JT, Filppula AM, Niemi M, et al. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68:168–241.
   PubMed Web of Science ®Google Scholar
• Backes JM, Gibson CA, Ruisinger JF, et al. Fibrates: what have we learned in the past 40 years? Pharmacotherapy. 2007;27:412–424.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 1987;83:9–20.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565–581.
   PubMed Web of Science ®Google Scholar
• Mano Y, Usui T, Kamimura H. The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007;35:2040–2044.
   PubMed Web of Science ®Google Scholar
• Kimoto E, Li R, Scialis RJ, et al. Hepatic disposition of gemfibrozil and its major metabolite gemfibrozil 1-O-β-glucuronide. Mol Pharm. 2015;12:3943–3952.
   PubMed Web of Science ®Google Scholar
• Sallustio BC, Fairchild BA, Shanahan K, et al. Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab Dispos. 1996;24:984–989.
   PubMed Web of Science ®Google Scholar
• Spencer CM, Barradell LB. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs. 1996;51:982–1018.
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen M, et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther. 2008;84:403–411.
   PubMed Web of Science ®Google Scholar
• Backman JT, Honkalammi J, Neuvonen M, et al. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos. 2009;37:2359–2366.
   PubMed Web of Science ®Google Scholar
• Baer BR, DeLisle RK, Allen A. Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem Res Toxicol. 2009;22:1298–1309.
   PubMed Web of Science ®Google Scholar
• Jenkins SM, Zvyaga T, Johnson SR, et al. Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil. Drug Metab Dispos. 2011;39:2421–2430.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280–1287.
   PubMed Web of Science ®Google Scholar
• Wen X, Wang JS, Backman JT, et al. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos. 2001;29:1359–1361.
   PubMed Web of Science ®Google Scholar
• Fujino H, Shimada S, Yamada I, et al. Studies on the interaction between fibrates and statins using human hepatic microsomes. Arzneimittelforschung. 2003;53:701–707.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica. 2007;37:1225–1256.
   PubMed Web of Science ®Google Scholar
• Silverman RB. Mechanism-based enzyme inactivators. Methods Enzymol. 1995;249:240–283.
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35:361–390.
   PubMed Web of Science ®Google Scholar
• Gan J, Chen W, Shen H, et al. Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010;70:870–880.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, et al. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34:1229–1236.
   PubMed Web of Science ®Google Scholar
• Nakagomi-Hagihara R, Nakai D, Tokui T, et al. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica. 2007;37:474–486.
   PubMed Web of Science ®Google Scholar
• Vildhede A, Karlgren M, Svedberg EK, et al. Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos. 2014;42:1210–1218.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Li B, Louie SW, et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica. 2005;35:737–753.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Watanabe T, et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011;39:1031–1038.
   PubMed Web of Science ®Google Scholar
• Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130:1793–1806.
   PubMed Web of Science ®Google Scholar
• Noé J, Portmann R, Brun M-E, et al. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007;35:1308–1314.
   PubMed Web of Science ®Google Scholar
• Pedersen JM, Matsson P, Bergström CAS, et al. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013;136:328–343.
   PubMed Web of Science ®Google Scholar
• Hinton LK, Galetin A, Houston JB. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res. 2008;25:1063–1074.
   PubMed Web of Science ®Google Scholar
• Shen H, Yang Z, Mintier G, et al. Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation. J Pharmacol Exp Ther. 2013;344:673–685.
   PubMed Web of Science ®Google Scholar
• Kivistö KT, Zukunft J, Hofmann U, et al. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:124–130.
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Backman JT, Neuvonen PJ. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59:433–439.
   PubMed Web of Science ®Google Scholar
• Bidstrup TB, Bjørnsdottir I, Sidelmann UG, et al. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol. 2003;56:305–314.
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Laitila J, Neuvonen PJ, et al. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol. 2005;97:249–256.
   PubMed Web of Science ®Google Scholar
• Säll C, Houston JB, Galetin A. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab Dispos. 2012;40:1279–1289.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003;46:347–351.
   PubMed Web of Science ®Google Scholar
• Suttle AB, Grossmann KF, Ouellet D, et al. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol. 2015;55:392–400.
   PubMed Web of Science ®Google Scholar
• Johnson BM, Stier BA, Caltabiano S. Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. Clin Pharmacol Drug Dev. 2014;3:109–117.
   PubMed Web of Science ®Google Scholar
• Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63:20–29.
   PubMed Web of Science ®Google Scholar
• Macha S, Koenen R, Sennewald R, et al. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers. Clin Ther. 2014;36:280–290.e1.
   PubMed Web of Science ®Google Scholar
• Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54:1057–1069.
   PubMed Web of Science ®Google Scholar
• Niemi M, Neuvonen PJ, Kivistö KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001;70:439–445.
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, et al. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. Eur J Clin Pharmacol. 2007;63:463–469.
   PubMed Web of Science ®Google Scholar
• Filppula AM, Tornio A, Niemi M, et al. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clin Pharmacol Ther. 2013;94:383–393.
   PubMed Web of Science ®Google Scholar
• Niemi M, Tornio A, Pasanen MK, et al. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol. 2006;62:463–472.
   PubMed Web of Science ®Google Scholar
• Karonen T, Filppula A, Laitila J, et al. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther. 2010;88:223–230.
   PubMed Web of Science ®Google Scholar
• Deng L-J, Wang F, Li H-D. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol. 2005;61:831–836.
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005;77:404–414.
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Kosmiski LA, Bourne DWA, et al. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013;75:217–226.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Granfors M, et al. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia. 2003;46:1319–1323.
   PubMed Web of Science ®Google Scholar
• Arun KP, Meda VS, Kucherlapati VS, et al. Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. Eur J Clin Pharmacol. 2012;68:709–714.
   PubMed Web of Science ®Google Scholar
• Clinical pharmacology and biopharmaceutics review(s): Tyvaso. Food and Drug Administration/Center for Drug Evaluation and Research. 2009 [cited 2016 Jan 29]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf
   Google Scholar
• Kajosaari LI, Niemi M, Backman JT, et al. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther. 2006;79:231–242.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS, Gaman EA, et al. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos. 2005;33:413–418.
   PubMed Web of Science ®Google Scholar
• Filppula AM, Laitila J, Neuvonen PJ, et al. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos. 2011;39:904–911.
   PubMed Web of Science ®Google Scholar
• Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999;48:424–432.
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Laitila J, Neuvonen PJ, et al. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006;99:44–51.
   PubMed Web of Science ®Google Scholar
• Filppula AM, Laitila J, Neuvonen PJ, et al. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012;165:2787–2798.
   PubMed Web of Science ®Google Scholar
• Filppula AM, Neuvonen M, Laitila J, et al. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos. 2013;41:50–59.
   PubMed Web of Science ®Google Scholar
• Tornio A, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol. 2006;62:645–651.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16:873–879.
   PubMed Web of Science ®Google Scholar
• Tornio A, Vakkilainen J, Neuvonen M, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenet Genomics. 2015;25:382–387.
   PubMed Web of Science ®Google Scholar
• Bergman E, Matsson EM, Hedeland M, et al. Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. J Clin Pharmacol. 2010;50:1039–1049.
   PubMed Web of Science ®Google Scholar
• Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 1995;76:80A–83A.
   PubMed Web of Science ®Google Scholar
• Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010;87:130–133.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006;80:356–366.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157–181.
   PubMed Web of Science ®Google Scholar
• Varma MV, Lin J, Bi YA, et al. Quantitative rationalization of gemfibrozil drug interactions: consideration of transporters-enzyme interplay and the role of circulating metabolite gemfibrozil 1-O-beta-glucuronide. Drug Metab Dispos. 2015;43:1108–1118.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Juntti-Patinen L, et al. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol. 2005;60:208–217.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol. 2010;107:775–781.
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, et al. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci. 2012;33:312–322.
   PubMed Web of Science ®Google Scholar
• Kudo T, Hisaka A, Sugiyama Y, et al. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. Drug Metab Dispos. 2013;41:362–371.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Maeda K, Sugiyama Y. Transporter-mediated drug–drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther. 2012;91:1053–1064.
   PubMed Web of Science ®Google Scholar
• Honkalammi J, Niemi M, Neuvonen PJ, et al. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos. 2011;39:1977–1986.
   PubMed Web of Science ®Google Scholar
• Varma MVS, Lai Y, Kimoto E, et al. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res. 2013;30:1188–1199.
   PubMed Web of Science ®Google Scholar
• Busse KH, Hadigan C, Chairez C, et al. Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. J Acquir Immune Defic Syndr. 2009;52:235–239.
   PubMed Web of Science ®Google Scholar
• Honkalammi J, Niemi M, Neuvonen PJ, et al. Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther. 2011;89:579–586.
   PubMed Web of Science ®Google Scholar
• Ibarra-Barrueta O, Palacios-Zabalza I, Mora-Atorrasagasti O, et al. Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events. Ann Pharmacother. 2014;48:145–148.
   PubMed Web of Science ®Google Scholar
• Kazmi F, Barbara JE, Yerino P, et al. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab Dispos. 2015;43:523–533.
   PubMed Web of Science ®Google Scholar
• Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539–540.
   PubMed Web of Science ®Google Scholar
• Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994;54:5543–5546.
   PubMed Web of Science ®Google Scholar
• Tan AR, Dowlati A, Stein MN, et al. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. Br J Cancer. 2014;110:2647–2654.
   PubMed Web of Science ®Google Scholar
• Tornio A, Filppula AM, Kailari O, et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther. 2014;96:498–507.
   PubMed Web of Science ®Google Scholar
• Bergmann TK, Filppula AM, Launiainen T, et al. Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma. Br J Clin Pharmacol. 2016;81:313–315.
   PubMed Web of Science ®Google Scholar
• Sane RS, Ramsden D, Sabo JP, et al. Contribution of major metabolites towards complex drug-drug interactions of deleobuvir: in vitro predictions and in vivo outcomes. Drug Metab Dispos. 2015 [cited 2015 Dec 18]. DOI:10.1124/dmd.115.066985
   Web of Science ®Google Scholar
• Floyd JS, Kaspera R, Marciante KD, et al. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin Pharmacol Ther. 2012;91:896–904.
   PubMed Web of Science ®Google Scholar
• Kazmi F, Smith B, Hvenegaard MG, et al. Identification of a novel carbamoyl glucuronide as a metabolism-dependent inhibitor of CYP2C8. 9th International ISSX Meeting; 2010 Sep 4–8; Istanbul, Turkey. 2010 [cited 2016 Feb 2]. Available from: https://issx.confex.com/issx/intl9/webprogram/Paper21723.html
   Google Scholar
• Karlgren M, Ahlin G, Bergström CAS, et al. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res. 2012;29:411–426.
   PubMed Web of Science ®Google Scholar
• Taxak N, Bharatam PV. 2D QSAR study for gemfibrozil glucuronide as the mechanism-based inhibitor of CYP2C8. Indian J Pharm Sci. 2013;75:680–687.
   PubMed Web of Science ®Google Scholar